• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Demographic Insights into Migraine Prevalence and a Cost-Effective Analysis of Various Prophylactic Medications
  • VIEWS 2074
  • PDF 1396

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v22.4.60

Year: 2023, Volume: 22, Issue: 4, Pages: 186-191

Original Article

Demographic Insights into Migraine Prevalence and a Cost-Effective Analysis of Various Prophylactic Medications

Divya Saran1,*, Lokendra Sharma2, Alka Bansal3, Susheel Kumar4, Rajveer Singh Rathore5, Priyanka Joshi6

1Senior Demonstrator, Department of Pharmacology, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan
2PHOD, Department of Pharmacology, RUHS College of Medical Sciences, Jaipur, Rajasthan
3Professor, Department of Pharmacology, RUHS College of Medical Sciences, Jaipur, Rajasthan
4Assistant Professor, Department of Pharmacology, RUHS College of Medical Sciences, Jaipur, Rajasthan
5Senior Demonstrator, Department of Pharmacology, RUHS College of Medical Sciences, Jaipur, Rajasthan
6Vinayak Dental Care, Sujangarh, Churu.

*Corresponding author email: [email protected]

Creative Commons License

Abstract

Headache, a common human experience, has been classified since antiquity. Migraine, a prevalent disabling primary headache condition, has significant personal and societal consequences. Understanding its demography is critical for creating effective prevention and treatment methods. An observational study of 387 persons with chronic migraine was conducted over a six-month period. They were divided into three groups and given a separate prophylactic drug. Demographic information was collected at the outset, and patients were assessed at 4, 8, and 12 weeks. The study population had an average age of 38.20 ±12.78 years, with 90% of the participants being female. Migraine was most common in those under 30 (37%), followed by those between 31 and 40 (28%). The most common co-morbidity (43.5%) was anxiety. Propranolol alone was the most cost-effective preventative medication, followed by propranolol plus escitalopram. This study sheds light on the intricate relationship between migraine and demographic characteristics, underlining the significance of individualized care. Because females are more vulnerable, age-specific therapies are critical, as are gender-sensitive approaches. The potential benefits of preventative drugs in decreasing both personal and society burdens are highlighted by socioeconomic factors and cost-effectiveness analyses. To optimize outcomes and cost allocation, this study advocates for a patient-centered, comprehensive approach to migraine care.

Keywords

Migraine, Prevalence, Prophylactic Medications, Demographics, Cost­effectiveness Analysis

References

  1. Paul R, William JM. Headache. The American Journal of Medicine. 2018;131(1):17–24. Available from: https://doi.org/10.1016/j.amjmed.2017.09.005
  4. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lantéri–minet M, et al. Prevalence and clinical characteristics of migraine in France. Neurology. 2002;59(2):232–237. Available from: https://doi.org/10.1212/WNL.59.2.232
  5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. Headache: The Journal of Head and Face Pain. 2001;41(7):646–657. Available from: https;//doi.org/10.1046/j.1526-4610.2001.041007646.x
  6. Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK, et al. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol India. 2017 ;65(6):1280–1288. Available from: https://doi.org/10.4103/0028-3886.217979
  7. Khan J, Asoom LIA, Sunni AA, Rafique N, Latif R, Saif SA, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomedicine & Pharmacotherapy. 2021;139:111557. Available from: https://doi.org/10.1016/j.biopha.2021.111557
  8. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. 2019. Available from: https://doi.org/10.1016/j.ncl.2019.06.001
  9. Friedman BW, Grosberg BM. Diagnosis and Management of the Primary Headache Disorders in the Emergency Department Setting. Emergency Medicine Clinics of North America. 2009;27(1):71–87. Available from: https://doi.org/10.1016/j.emc.2008.09.005
  10. Law HZZ, Chung MH, Nissan G, Janis JE, Amirlak B. Hospital Burden of Migraine in United States Adults: A 15-year National Inpatient Sample Analysis. Plastic and Reconstructive Surgery - Global Open. 2020;8(4):e2790. Available from: https://doi.org/10.1097/GOX.0000000000002790
  11. Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, et al. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. Research Square Platform LLC. 2022. Available from: https://doi.org/10.1186/s10194-022-01492-y
  12. Ong JJY, Felice MD. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. Neurotherapeutics. 2018;15(2):274–290. Available from: https://doi.org/10.1007/s13311-017-0592-1
  13. Gorukanti DR, Rajneesh V, Sumalatha N, Karunakar CH. Comparison of Propranolol versus Amitriptyline as monotherapy for migraine prophylaxis. International journal of health sciences. 2022;6(S1):7379–7387. Available from: https://media.neliti.com/media/publications/429950-comparison-of-propranolol-versus-amitrip-a141a4eb.pdf
  15. Singh G, Sharma M, Kumar GA, Rao NG, Prasad K, Mathur P, et al. The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990–2019. The Lancet Global Health. 2021;9(8):e1129–e1144. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00164-9/fulltext
  16. Angra M, Bhardwaj A, Sharma A, Kumar G, Singh M, Kaur G, et al. Is Single-Drug Prophylaxis in Migraine Prevention a Better Option than Combination Therapy? An Observational Study in a Rural Tertiary Care Center in North West India. Journal of Neurosciences in Rural Practice. 2019;10(03):479–482. Available from: https://doi.org/10.1055/s-0039-1698282
  17. Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurological Sciences. 2021;42(12):5373–5376. Available from: https://doi.org/10.1007/s10072-021-05547-x
  18. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache: The Journal of Head and Face Pain. 2015;55(1):21–34. Available from: https://doi.org/10.1111/head.12482
  19. Müller KI, Alstadhaug KB, Bekkelund SI. Acceptability, feasibility, and cost of telemedicine for nonacute headaches: a randomized study comparing video and traditional consultations. Journal of medical Internet research. 2016;18(5):140. Available from: https://doi.org/10.2196/jmir.5221
  20. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2015;85(5):459–466. Available from: https://doi.org/10.1212/01.wnl.0000252808.97649.21
  22. Araújo CM, Barbosa IG, Lemos SM, Domingues RB, Teixeira AL. Cognitive impairment in migraine: a systematic review. Dementia & Neuropsychologia. 2012;6:74–83. Available from: https://doi.org/10.1590/S1980-57642012DN06020002
  23. Singla M, Sulena, Brar J, Kale R, Kale S. Clinical profile of migraine in a rural population presenting to Tertiary Care Hospital in North India. Annals of Indian Academy of Neurology. 2020;23(6):781. Available from: https://doi.org/10.4103/aian.AIAN_671_19
  24. Kim DD, Basu A. How does cost-effectiveness analysis inform health care decisions. AMA Journal of Ethics. 2021;23(8):639–686. Available from: https://doi.org/10.1001/amajethics.2021.639
  25. Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. The Journal of Headache and Pain. 2015;16(1):1–3. Available from: https://doi.org/10.1186/s10194-015-0496-6

Copyright

© 2023 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 04 March 2024

Year: 2023, Volume: 22, Issue: 4


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.